The King of Ozempic Is Scared as Hell

El Pais

Lean Left

Factuality

Ownership

Novo Nordisk, Europe's largest capitalisation company, has achieved worse results than expected in its new slimming drug: Cagrisema

redaccionmedica.com

Factuality

Ownership

"Ozempic's unexpected increase in demand has presented a challenge in the availability of treatment for people with diabetes, who depend on this medication to control their disease." This was assured by Francisco Pajuelo, medical director of Novo Nordisk Spain, who has pointed out to Medical Writing the measures they have taken from the company to ensure that both people with type 2 diabetes and those with obesity or overweight have adequate the…